Market Reports
sssadadasd
1 min readWelcome to the weekly market update from IFX payments. The global economy was allowed a brief sigh of relief this morning as big movements were made in the US and China trade talks. Read on to find out more. Current rates Currency pair Rate eur usd 1.1099 gbp eur 1.1864 gbp usd 1.3170 Rates correct as […]
Read moreIFX Market Report: Tuesday 20th April 2021
2 min readSterling had a stellar start to the week, enabling Cable to go above and beyond the 1.39 handle.
IFX Market Report: Monday 19th April 2021
2 min readAs risk appetite soared Sterling was the most benefited from the market’s sentiment, recovering from an intraday low of 1.3715 on Friday to hit a weekly high of 1.3842, closing it a handful of pips below the level.
IFX Market Report: Friday 16th April 2021
2 min readCable was able to gain more positive traction for the 4th consecutive session on Thursday as a subdued Dollar enabled the rate to press towards the 1.38 handle.
IFX Market Report: Thursday 15th April 2021
2 min readMarkets saw little excitement on Wednesday as nearly all major G10’s remained relatively rangebound.
IFX Market Report: Wednesday 14th April 2021
2 min readEURUSD is trading strong this morning as it attempts to push towards the 1.20 handle. The US Dollar Index (DXY) is down today, sinking to levels not seen since March 22.
IFX Market Report: Tuesday 13th April 2021
2 min readDespite the lifting of restrictions in the UK yesterday, the British Pound was unable to make any real substantial gains against the Euro or Dollar.
IFX Market Report: Monday 12th April 2021
2 min readLast week was tough for Sterling, with the currency recording its worst week since September 2020 against the Euro.
IFX Market Report: Friday 9th April 2021
2 min readThursday proved to a rather uneventful day for markets, with rates trading flat for most of the day.
IFX Market Report: Thursday 8th April 2021
2 min readSterling experienced its second session of losses yesterday, falling significantly against the Euro and Dollar due to issues surrounding the Oxford-AstraZeneca vaccine.